biotech investing Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
biotech investing Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
biotech investing Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
biotech investing Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
biotech investing Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
biotech investing Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
biotech investing Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
biotech investing Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.